Liquidia falls after United Therapeutics files new patent suit over inhaled drug

Liquidia

12/05/2025 11:47

** Shares of biopharma firm Liquidia Corp LQDA.O fall 5% to $14.50 premarket

** United Therapeutics Corporation UTHR.O filed a litigation  against Liquidia on May 9 in the U.S. District Court of North Carolina, alleging infringement of U.S. Patent, LQDA says

** The lawsuit seeks to block Liquidia from launching its inhaled drug, Yutrepia, if approved by the FDA

** Liquidia has faced multiple delays to bringing Yutrepia to the U.S. market

** The drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension (PAH), but Liquidia could not market it due to a regulatory stay related to a patent infringement dispute with United

** Company says the new lawsuit does not affect the FDA's ability to make a final decision on Yutrepia by May 24

** As of last close, LQDA was up ~30%

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))